PE20090654A1 - Formulaciones galenicas que contienen alisquireno y valsartan - Google Patents

Formulaciones galenicas que contienen alisquireno y valsartan

Info

Publication number
PE20090654A1
PE20090654A1 PE2008001660A PE2008001660A PE20090654A1 PE 20090654 A1 PE20090654 A1 PE 20090654A1 PE 2008001660 A PE2008001660 A PE 2008001660A PE 2008001660 A PE2008001660 A PE 2008001660A PE 20090654 A1 PE20090654 A1 PE 20090654A1
Authority
PE
Peru
Prior art keywords
alisquiren
weight
valsartan
amount
formulations containing
Prior art date
Application number
PE2008001660A
Other languages
English (en)
Spanish (es)
Inventor
Ralf Altenburger
Maggy Babiole Saunier
Nicole Bargenda
Michaela Anna Maria Bock
Sabine Adler
Bruno Buss
Catherine Curdy
Indrajit Ghosh
Stefan Hirsch
Patrice Francois Keller
Charu Kochhar
Shoufeng Li
Nicoletta Loggia
Amol Singh Matharu
Julien Taillemite
Wei-Qin Tong
Sudha Vippagunta
Hong Wen
Marie-Christine Wolf
Jay Parthiban Lakshman
James Kowalski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090654A1 publication Critical patent/PE20090654A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2008001660A 2007-09-28 2008-09-24 Formulaciones galenicas que contienen alisquireno y valsartan PE20090654A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97592507P 2007-09-28 2007-09-28
US97590107P 2007-09-28 2007-09-28
US97591907P 2007-09-28 2007-09-28
US97590907P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
PE20090654A1 true PE20090654A1 (es) 2009-06-27

Family

ID=40377183

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001660A PE20090654A1 (es) 2007-09-28 2008-09-24 Formulaciones galenicas que contienen alisquireno y valsartan

Country Status (18)

Country Link
US (1) US20100209480A1 (enExample)
EP (1) EP2205233A2 (enExample)
JP (1) JP2010540547A (enExample)
KR (1) KR20100063090A (enExample)
CN (1) CN101808631A (enExample)
AR (1) AR066168A1 (enExample)
AU (1) AU2008309058B2 (enExample)
BR (1) BRPI0817442A2 (enExample)
CA (1) CA2698330A1 (enExample)
CL (1) CL2008002829A1 (enExample)
CO (1) CO6270217A2 (enExample)
EC (1) ECSP10010052A (enExample)
MA (1) MA31706B1 (enExample)
MX (1) MX2010003441A (enExample)
PE (1) PE20090654A1 (enExample)
TN (1) TN2010000135A1 (enExample)
TW (1) TW200924737A (enExample)
WO (1) WO2009045795A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697229A1 (en) * 2007-09-28 2009-04-02 Novartis Ag Galenical formulations of organic compounds
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2010107966A1 (en) * 2009-03-20 2010-09-23 Novartis Ag Pharmaceutical composition comprising aliskiren
US20120009257A1 (en) * 2009-03-20 2012-01-12 Indrajit Ghosh Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren
WO2011116115A1 (en) * 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
KR20140076621A (ko) * 2011-10-12 2014-06-20 다우 글로벌 테크놀로지스 엘엘씨 사출 성형된 투여형
MX2014007933A (es) * 2011-12-26 2014-07-30 Novartis Ag Comprimidos y agentes recubiertos en seco.
CN103349652B (zh) * 2013-05-11 2014-11-19 辽宁大学 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法
EP4320233A4 (en) 2021-04-07 2025-08-13 Battelle Memorial Institute RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
BRPI0516128A (pt) * 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
CN101166523A (zh) * 2005-04-27 2008-04-23 诺瓦提斯公司 治疗动脉粥样硬化的方法

Also Published As

Publication number Publication date
ECSP10010052A (es) 2010-04-30
CO6270217A2 (es) 2011-04-20
MA31706B1 (fr) 2010-09-01
CA2698330A1 (en) 2009-04-09
WO2009045795A3 (en) 2009-07-16
US20100209480A1 (en) 2010-08-19
JP2010540547A (ja) 2010-12-24
MX2010003441A (es) 2010-04-21
WO2009045795A2 (en) 2009-04-09
AR066168A1 (es) 2009-07-29
TN2010000135A1 (en) 2011-09-26
CL2008002829A1 (es) 2009-06-26
KR20100063090A (ko) 2010-06-10
AU2008309058A1 (en) 2009-04-09
AU2008309058B2 (en) 2012-08-09
TW200924737A (en) 2009-06-16
BRPI0817442A2 (pt) 2015-06-16
CN101808631A (zh) 2010-08-18
EP2205233A2 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
PE20090654A1 (es) Formulaciones galenicas que contienen alisquireno y valsartan
PE20130340A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp)
PE20120542A1 (es) Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
PE20140252A1 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf
ATE483707T1 (de) 2-cyclopropylthiazolderivate
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
PE20141072A1 (es) Composiciones farmaceuticas de accion doble basadas en el bloqueo de los receptores de angiotensina y la inhibicion de la endopeptidasa neutral
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
AR070018A1 (es) 5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il sulfamida, composiciones farmaceuticas que lo contienen, metodo de preparacion y uso del mismo en enfermedades asociadas al aumento de la vasoconstriccion, proliferacion o inflamacion debidas a endotelina, tales como insuficien
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
CL2011001091A1 (es) Forma de dosificacion farmaceutica oral solida que comprende en su nucleo nifedipino o nisoldipino y en un revestimiento de manto alrededor del nucleo al menos un antagonista de angiotensina ii y/o al menos un diuretico; procedimiento para su preparacion, util para tratar hipertension.
PE20120018A1 (es) Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
CL2007001597A1 (es) Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
MX2012006106A (es) Composiciones farmaceuticas que comprenden ligandos de receptores sigma.
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
PE20110943A1 (es) Formulacion oral solida de alisquireno
SV2010003723A (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina
CR20110093A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
CO6612226A2 (es) Tableta
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)

Legal Events

Date Code Title Description
FC Refusal